BioCardia

BioCardia EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of BioCardia (BCDA) as of Nov 20, 2026 is -1.46. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -1.51 — a change of -3.35% (higher).

EV/EBIT

-1.46

YoY

-3.35%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of BioCardia is 2025 -1.46 . EV/EBIT (Enterprise Value to EBIT) of BioCardia was 2024 -1.51 . It decreases by -3.35% higher compared to the previous year.

The BioCardia EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
-0.82 USD
Jan 1, 2020
-0.78 USD
Jan 1, 2021
-0.96 USD
Jan 1, 2022
-1.02 USD
Jan 1, 2023
-1.04 USD
Jan 1, 2024
-1.51 USD
Jan 1, 2025
-1.46 USD
Jan 1, 2026 (e)
-1.98 USD
The BioCardia EV/EBIT history
YEAREV/EBITYoY
est-1.98+35.47%
-1.46-3.35%
-1.51+45.53%
-1.04+2.21%
-1.02+6.13%
-0.96+22.95%
-0.78-5.44%
-0.82-3.96%
-0.86-12.03%
-0.98-38.67%
-1.59-104.19%
37.93-27.59%
52.37+79.98%
29.10-5,117.24%
-0.58+56.76%
-0.37+184.62%
-0.13—
0.00—
0.00-100.00%
-0.01—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioCardia Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides BioCardia's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates BioCardia's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots BioCardia's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if BioCardia grows earnings faster than its peers.

BioCardia Stock analysis

What does BioCardia do? BioCardia, Inc. generates revenue through its clinical-stage regenerative medicine portfolio, primarily focused on CardiAMP and CardiALLO cell therapies. The CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure, targeting healthcare providers and clinical trial sponsors seeking advanced treatments for heart failure patients. CardiALLO, an allogeneic off-the-shelf mesenchymal stem cell product, is developed for broader therapeutic applications, appealing to hospitals and research institutions requiring ready-to-use regenerative solutions. The company also monetizes the Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products, which serve as complementary tools for medical professionals during therapeutic procedures. CardiAMP and CardiALLO are positioned as innovative therapeutic candidates targeting heart failure and regenerative medicine segments, with CardiAMP advancing toward potential commercialization in late-stage trials. The Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products cater to interventional cardiology and surgical markets, providing specialized equipment for clinicians. BioCardia's revenue streams are derived from partnerships with clinical trial sponsors and direct sales of medical devices to healthcare facilities, focusing on cardiovascular and regenerative medicine applications. The company's business model relies on developing and commercializing cell therapies and medical devices, with CardiAMP leading the portfolio in late-stage development. CardiALLO serves as a complementary allogeneic product, while the Helix and Morph products support procedural needs in cardiology. Revenue is anticipated from future commercialization of CardiAMP post-trial success and from ongoing sales of the Helix and Morph systems to medical institutions. BioCardia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioCardia stock

EV/EBIT (Enterprise Value to EBIT) of BioCardia is -1.46 in 2025.

EV/EBIT (Enterprise Value to EBIT) of BioCardia changed from -1.51 to -1.46, representing a -3.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) BioCardia since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s BioCardia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioCardia

All Key Metrics — BioCardia